-
公开(公告)号：US11083756B2
公开(公告)日：2021-08-10
申请号：US15608691
申请日：2017-05-30
发明人： Duncan J. Stewart , David Courtman , Seth Mount , Darryl Davis
摘要： Methods for generating serum-free and/or xenogen-free cardiac explant-derived stem cells (EDC) are provided. These methods may include providing an initial cardiac explant, which has been minced and digested; plating the initial cardiac explant; culturing the plated cardiac explant in serum-free and xenogen-free medium; harvesting EDC cells surrounding or emerging from the plated cardiac explant; and optionally performing static expansion of harvested EDC cells in serum-free and xenogen-free media. Serum-free and/or xenogen-free cardiac EDC cells produced by these methods, as well as methods and uses thereof for the treatment of heart failure in a subject in need thereof, are also provided.
-
公开(公告)号：US10943707B2
公开(公告)日：2021-03-09
申请号：US14426208
申请日：2012-10-26
发明人： Etienne Lefort , Vincenzo Teoli , Robert A. Dekemp , Ran Klein
摘要： Embodiments of the present invention provide for assessing the state of an 82Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of 82Rb, 82Sr, or 85Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a 82Sr/82Rb generator of the system may be halted so as to prevent a user from performing an end-run around these quality control mechanisms of the 82Rb elution system.
-
公开(公告)号：US20180296751A1
公开(公告)日：2018-10-18
申请号：US15953140
申请日：2018-04-13
发明人： Etienne Lefort , Vincenzo Teoli , Robert A. Dekemp , Ran Klein
摘要： Provided are 82Sr/82Rb elution systems that accept patient weight as a input function in order to determine an optimal quantity of radioactive rubidium-82 for delivery to a patient pursuant to an imaging scan. Also disclosed are systems that deliver a saline flush to remove residual 82Rb from the system downstream of the generator, and preferably deliver the removed residual 82Rb to the patient. Other disclosed systems measure the total volume of saline that flows through a 82Sr/82Rb generator, a total volume of saline that flows through the generator and through a bypass line, or a total volume of saline received by a waste reservoir, in order to monitor system components so that optimal system functioning is assured.
-
公开(公告)号：US20150228368A1
公开(公告)日：2015-08-13
申请号：US14426208
申请日：2012-10-26
发明人： Etienne Lefort , Vincenzo Teoli , Robert A. Dekemp , Ran Klein
CPC分类号： G21G1/0005 , F04B49/065 , G05B15/02
摘要： Embodiments of the present invention provide for assessing the state of an 82Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of 82Rb, 82Sr, or 85Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a 82Sr/82Rb generator of the system may be halted so as to prevent a user from performing an end-run around these quality control mechanisms of the 82Rb elution system.
摘要翻译： 本发明的实施方案提供了评估82Rb洗脱系统的状态。 在某些实施方案中，系统开始包括洗脱的评估，并且可以测量度量。 在从发生器洗脱的流体中，该度量可以是82Rb，82Sr或85Sr的浓度，从发生器洗脱的流体的体积或流过系统的至少一部分的流体的压力 。 如果评估完成，可以根据评估结果在用户界面上生成输出，该用户界面建议采取行动方案，或者不采取任何行动。 如果评估不能成功完成，因为系统中的82Sr / 82Rb发生器可能被停止，以防止用户围绕82Rb洗脱系统的这些质量控制机制进行终端运行。
-
公开(公告)号：US20240299642A1
公开(公告)日：2024-09-12
申请号：US18669992
申请日：2024-05-21
发明人： Robert A. deKemp
CPC分类号： A61M5/007 , A61B6/037 , A61B6/481 , A61B6/503 , A61B6/5264 , A61M5/1409 , A61M5/16813 , A61M5/16827
摘要： Disclosed are methods of radioisotope infusion comprising infusing saline comprising a diagnostic dose of a radioisotope, and delivering a pre-measured volume of push saline. The radioisotope may be 82Rb, 15O, 13N, 11C or 18F. The radioisotope is infused in the subject for imaging of the heart using Positron Emission Tomography imaging. The methods confer improved image quality with low background noise, higher signal to noise ratio (SNR) and higher contrast to noise ratio (CNR), leading to better diagnosis and thus eliminating the need of repeating the infusion and imaging which in turn reduces exposure of a patient to radiation.
-
公开(公告)号：US20240186017A1
公开(公告)日：2024-06-06
申请号：US18438599
申请日：2024-02-12
发明人： Louise Ying Pw SUN
摘要： A system and method are provided for predicting hemodynamic events. The method includes receiving current patient data, obtaining a current mean arterial pressure (MAP) value from the current patient data, and obtaining prior MAP data obtained from the patient during a period of care. The method also includes using the current MAP value, the past MAP data, a predetermined MAP threshold, and at least one trained model to predict a hemodynamic event, each trained model corresponding to a prediction interval to determine whether the hemodynamic event is expected to occur within a window of time; and outputting an alert indicative of the hemodynamic event to a device configured to display a graphical user interface comprising the alert.
-
公开(公告)号：US11497832B2
公开(公告)日：2022-11-15
申请号：US16610459
申请日：2018-05-04
发明人： Marc Ruel , Erik Suuronen , Emilio Alarcon
IPC分类号： A61K31/726 , A61L27/52 , A61K38/39 , A61L27/20 , A61L27/24
摘要： Provided herein are biocompatible and/or biodegradable hydrogel compositions comprising native collagen and chondroitin sulfate, the collagen and chondroitin sulfate being chemically cross-linked thereby forming a matrix. The native collagen may comprise recombinant human collagen type I (rHCI), recombinant human collagen type III (rHCIII), or a combination thereof, for example. Methods and uses thereof for regeneration or repair of tissue, improvement of tissue function, mechanical stabilization of tissue, prevention of tissue damage, or prevention of tissue loss of function are described, particularly with respect to cardiac tissue and myocardial infarction events.
-
公开(公告)号：US20220347377A1
公开(公告)日：2022-11-03
申请号：US17849372
申请日：2022-06-24
发明人： Etienne LEFORT , Vincenzo TEOLI , Robert A. DEKEMP , Ran KLEIN
摘要： Provided are 82Sr/82Rb elution systems that accept patient weight as a input function in order to determine an optimal quantity of radioactive rubidium-82 for delivery to a patient pursuant to an imaging scan. Also disclosed are systems that deliver a saline flush to remove residual 82Rb from the system downstream of the generator, and preferably deliver the removed residual 82Rb to the patient. Other disclosed systems measure the total volume of saline that flows through a 82Sr/82Rb generator, a total volume of saline that flows through the generator and through a bypass line, or a total volume of saline received by a waste reservoir, in order to monitor system components so that optimal system functioning is assured.
-
公开(公告)号：US20160324992A1
公开(公告)日：2016-11-10
申请号：US15147495
申请日：2016-05-05
IPC分类号： A61K51/04 , A61K47/48 , A61K31/4178
CPC分类号： A61K51/0453 , A61K31/4178 , A61K31/7105 , A61K51/0446
摘要： A method of detecting an atherosclerotic plaque vulnerable to rupture in a subject comprises providing to the subject a labelled necrostatin or a derivative thereof, and visualizing the label, wherein a localization of the label in a plaque indicates the plaque is vulnerable to rupture. A method of detecting and treating an atherosclerotic plaque vulnerable to rupture comprises providing to the subject a labelled necrostatin or a derivative thereof, visualizing the label, wherein a localization of the label in a plaque indicates the plaque is vulnerable to rupture; and providing a necroptosis inhibitor or derivative thereof to the subject when the visualizing indicates that the plaque is vulnerable to rupture. The necroptosis inhibitor may comprise a necrostatin, such as Nec-1. The label may be a radiolabel such as 123I. By visualizing plaques vulnerable to rupture, atherosclerotic plaques may be identified and treated in advance of rupture.
摘要翻译： 一种检测易受受试者破裂的动脉粥样硬化斑块的方法包括向受试者提供标记的抑制剂或其衍生物，并使标签可视化，其中标记物在斑块中的定位表明斑块易于破裂。 一种检测和治疗易于破裂的动脉粥样硬化斑块的方法包括向受试者提供标记的灭菌素或其衍生物，使标签可视化，其中标记物在斑块中的定位表明斑块易于破裂; 并且当可视化表明斑块容易破裂时，向受试者提供一种死囊虫抑制剂或其衍生物。 人工死亡抑制剂可以包含灭蚊剂，例如Nec-1。 该标签可以是放射性标记如123I。 通过使容易破裂的斑块可视化，可以在断裂之前鉴定和治疗动脉粥样硬化斑块。
-
公开(公告)号：US20130337041A1
公开(公告)日：2013-12-19
申请号：US13776515
申请日：2013-02-25
发明人： Daniel L. SPARKS
IPC分类号： A61K31/685 , A61K31/683
CPC分类号： A61K31/685 , A61K31/66 , A61K31/663 , A61K31/683 , A61K2300/00
摘要： The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins.
摘要翻译： 本发明提供包含合成或天然存在的带电磷脂的药物组合物，其被配制成用于给予受试者或作为食物添加剂施用的剂型。 负电荷的磷脂组合物增加血管内脂蛋白的净负电荷，增强胆固醇的清除率并调节脂肪分解酶的功能，阻止凝血酶原的形成，并帮助清除病毒和细菌颗粒。 因此，负电荷的脂质组合物可以施用于人和动物用于治疗高脂血症和凝血障碍并降低血流中的病毒，细菌和内毒素的水平。 可以施用带正电的脂质组合物以延迟来自血浆隔室的脂蛋白清除，并为与脂蛋白相关的药物提供更长的活性持续时间。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.019 秒)
